Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Cullinan Oncology stock

Own Cullinan Oncology stock in just a few minutes.

Cullinan Oncology, Inc is an other business based in the US. Cullinan Oncology shares (CGEM) are listed on the NASDAQ and all prices are listed in US Dollars. Cullinan Oncology employs 24 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Cullinan Oncology

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CGEM – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Cullinan Oncology share price

Use our graph to track the performance of CGEM stocks over time.

Cullinan Oncology shares at a glance

Information last updated 2021-04-30.
52-week range$27.01 - $59.85
50-day moving average $37.79
200-day moving average $38.99
Wall St. target price$47.75
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) N/A

Buy Cullinan Oncology shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Cullinan Oncology stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Cullinan Oncology financials

Gross profit TTM $0
Return on assets TTM -23.93%
Return on equity TTM -39.88%
Profit margin 0%
Book value N/A
Market capitalisation $1.4 billion

TTM: trailing 12 months

Shorting Cullinan Oncology shares

There are currently 2.1 million Cullinan Oncology shares held short by investors – that's known as Cullinan Oncology's "short interest". This figure is 1% down from 2.1 million last month.

There are a few different ways that this level of interest in shorting Cullinan Oncology shares can be evaluated.

Cullinan Oncology's "short interest ratio" (SIR)

Cullinan Oncology's "short interest ratio" (SIR) is the quantity of Cullinan Oncology shares currently shorted divided by the average quantity of Cullinan Oncology shares traded daily (recently around 385891.09090909). Cullinan Oncology's SIR currently stands at 5.5. In other words for every 100,000 Cullinan Oncology shares traded daily on the market, roughly 5500 shares are currently held short.

To gain some more context, you can compare Cullinan Oncology's short interest ratio against those of similar companies.

However Cullinan Oncology's short interest can also be evaluated against the total number of Cullinan Oncology shares, or, against the total number of tradable Cullinan Oncology shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cullinan Oncology's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Cullinan Oncology shares in existence, roughly 50 shares are currently held short) or 0.1011% of the tradable shares (for every 100,000 tradable Cullinan Oncology shares, roughly 101 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Cullinan Oncology.

Find out more about how you can short Cullinan Oncology stock.

Cullinan Oncology share dividends

We're not expecting Cullinan Oncology to pay a dividend over the next 12 months.

You may also wish to consider:

Cullinan Oncology overview

Cullinan Management, Inc. , a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Management, Inc.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site